16 results about "H1n1 virus" patented technology

The invention provides a Raman enhanced nano-label based on a polydopamine core-shell structure, a preparation method and application of the Raman enhanced nano-label in immunochromatography, and relates to the technical field of immunochromatography. The Raman enhanced nano-label based on the polydopamine core-shell structure sequentially comprises a PDA microsphere core, a PEI layer and a gold and silver nano-particle layer from inside to outside, the gold and silver nanoparticle layer is gold and silver nanoparticles with a core-shell structure; the gold and silver nanoparticle layer is connected with a Raman signal molecule DTNB, and a terminal carboxyl group of the Raman signal molecule DTNB is coupled with a capture antibody of an H1N1 virus or a capture antibody of an SARS-CoV-2 virus. The nano-label has colorimetric and SERS enhanced activity at the same time, has the advantages of rich hot spots, high stability, excellent optical performance and the like, is used for an immunochromatography sensor to detect two respiratory viruses at the same time, adopts qualitative and quantitative dual-mode detection, and improves the detection flexibility, sensitivity and accuracy.

The invention discloses THK01 and derivatives thereof, a preparation method and application of THK01 and derivatives thereof in preparation of anti-inflammatory drugs, and the THK01 and derivatives thereof are prepared by performing a series of chemical reactions on o-nitrobenzaldehyde containing a specific substituent group, including Wittig reaction, Diels-Alder reaction, Cadolan reaction, Fischer indole synthesis reaction, demethylation reaction, reduction reaction, click chemical reaction and the like. The THK01 structure modified derivatives with different substituent groups are obtained. The THK01 structure modified derivative disclosed by the invention is diversified in synthetic route and high in reaction success rate; in-vitro and in-vivo experiments show that the compounds can significantly inhibit NO generation and inflammatory response at low concentration, and can effectively treat inflammatory bowel disease and acute pneumonia induced by H1N1 virus in an animal model. These findings provide valuable candidate compounds and new treatment strategies for developing novel, safe and efficient anti-inflammatory drugs.

The invention discloses a preparation method and application of an aptamer functionalized nano-enzyme probe for detecting H1N1 virus, and belongs to the technical field of biosensing and virus detection. The invention aims to solve the problem of limitation of the existing H1N1 virus detection method in sensitivity, specificity and stability. The preparation method comprises the following steps: 1, mixing and incubating a three-metal nickel-palladium-gold nano-enzyme solution containing a hollow structure and a sulfhydrylation H1N1 hemagglutinin protein specific recognition aptamer solution; and 2, sealing the surface. According to the application, the kit is used for detecting the H1N1 virus.

The present invention provides a tricyclic diterpenoid compound having anti-influenza virus activity. The tricyclic diterpenoid compound not only has better anti-H1N1 virus activity, but also is low in toxicity. The invention also discloses a preparation method of the tricyclic diterpenoid compound with antiviral activity. The preparation method comprises the following steps: (1) obtaining a fermentation product rich in the tricyclic diterpenoid compound through microbial fermentation culture; a recombinant vector adopted in the microbial fermentation culture carries nucleotide sequences: PQ793156 (dioxygenase gene), PQ793157 (FAD dependent monooxygenase gene), PQ793158 (terpenoid synthase gene), PQ793159 (UbiA family isopentenyl transferase gene), PQ793160 (GGPP synthase gene) and PQ793161 (amino transferase gene). And (2) separating and purifying the fermentation product obtained in the step (1) to obtain the tricyclic diterpenoid compound.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to preparation and application of beta-, gamma-or delta-aminoketone derivatives, the structure of the derivatives is shown as a general formula (I), in the formula, R1 is alkyl, aryl and the like; r2 represents an aryl group, a heteroaryl group, an alkynyl group, an alkenyl group, a cyano group or the like; r3 is hydrogen, alkyl, aryl or the like; r4 represents an aryl sulfonyl group, a heteroaryl sulfonyl group, an alkyl sulfonyl group, a sulfonate group or the like; in the structural formula, n represents the length of a carbon chain, and the value is 0-2. The derivative is novel in structure, has good antiviral activity, particularly has a good inhibition effect on H1N1 virus, and has great application potential in the aspect of antiviral effect; meanwhile, the preparation method has the advantages of few reaction steps, no need of metal catalysis, no need of complex substrate preparation, simplicity and safety in operation, mild reaction conditions, low cost, higher atom economy and high yield.

The application belongs to the technical field of organic electrochemical transistors, and discloses a p-type organic electrochemical transistor biosensor, a preparation method and application. The sensor comprises a first substrate and a second substrate. A source electrode is arranged on one side of the first substrate. A polymer semiconductor channel is arranged on the source electrode. A drain electrode is arranged on the polymer semiconductor channel. A first floating gate is arranged on the other side of the first substrate. The first substrate, the drain electrode and the first floating gate are covered with a first electrolyte layer. A gate electrode is arranged on one side of the second substrate. A gate modification layer is arranged on the gate electrode. A second floating gate is arranged on the other side of the second substrate. The second substrate, the gate modification layer and the second floating gate are covered with a second electrolyte layer. The first floating gate and the second floating gate are connected through a wire. The application realizes the detection of an ultralow concentration (10 ‑20 mol / L) H1N1 virus marker and realizes the detection of 10 ‑17 mol / L H1N1 virus marker in an ultrashort time.

The present invention provides a stilbene derivative of guaiazulene, which belongs to the technical field of medicinal chemistry. The present invention combines guaiazulene with a stilbene skeleton for pharmacophore combination to synthesize stilbene derivatives of guaiazulene. This structure contains guaiazulene functional units and stilbene skeleton functional units, which can give such compounds a wide range of anti-tumor and anti-influenza virus activities, laying the foundation for the development of stilbene derivatives of guaiazulene as anti-tumor and anti-influenza virus candidate drugs. The results of the examples show that the stilbene derivatives of guaiazulene provided by the present invention have certain inhibitory activity on human chronic myeloid leukemia cells K562, human breast cancer cells MDA-MB-231, and human pancreatic cancer cells ASPC-1; the stilbene derivatives of guaiazulene provided by the present invention have certain inhibitory activity on H1N1 virus, which is the first time that a compound with antiviral activity has been found from guaiazulene derivatives, broadening the direction of antiviral drug development.

The invention provides application of levistilide A in preparation of anti-influenza virus drugs, and belongs to the technical field of biological medicines. The influenza virus is an H1N1 virus. In-vitro anti-influenza experiments find that levistilide A can significantly inhibit infection of H1N1 virus and significantly improve cytopathy caused by influenza virus infection. The H1N1 virus half inhibitory concentration (IC50) of the levistilide A in MDCK cells is 1.462 M, and the H1N1 virus half inhibitory concentration (IC50) of the levistilide A in A549 cells is 0.455 M. The invention proves that the levistilactone A has a remarkable anti-H1NA virus effect, can be used for preparing the anti-influenza virus medicine, and has an excellent application prospect.

The invention concerns a microwave disinfection device (2) configured to destroy / inactivate the SARS-COV-2 and H1N1 viruses and comprising a microwave irradiation section (22) configured to: irradiate microwave signals that have an incident electric field amplitude not higher than 6 V / m and frequencies that are included in the 8-10 GHz band and are spaced from each other by a step comprised between 10 MHZ and 100 MHz; irradiate the microwave signals at each individual frequency for a time interval comprised between 50 ms and 1 s; and irradiate the microwave signals with duty cycles comprised between 5% and 50%.

The invention discloses an inorganic nano disinfectant and a preparation method thereof, and belongs to the technical field of nano materials and disinfection. The preparation method comprises the following steps: adding copper salt, zinc salt, silver salt and deionized water into a reaction kettle, and carrying out hydrothermal reaction to obtain a solution A; adding a surfactant and an alkaline pH regulator into the solution A, regulating the pH value of the solution, and carrying out heat preservation reaction to obtain a solution B; and adding an acidic pH regulator into the solution B to regulate the pH value of the solution, thereby obtaining the inorganic nano disinfectant. Microbial cell membranes and DNA / RNA are destroyed through metal ions, and the inactivation rates of H1N1 viruses, escherichia coli (ATCC 25922), staphylococcus aureus (ATCC 6538) and mites all reach 100%. Meanwhile, the pH is close to neutral, corrosion is avoided, and residual metal ions can be recycled through precipitation. According to the disinfectant prepared by the invention, low-concentration, broad-spectrum and long-acting disinfection of the disinfectant is realized by controllably synthesizing a nano-copper, zinc and silver composite system and combining pH regulation and surface modification technologies.

The present invention provides an influenza A (H1N1) virus lateral flow assay biosensor and its application, belonging to the field of detection. The influenza A (H1N1) virus lateral flow assay biosensor provided by the present invention comprises: primer Primer-9, template Template-9, Bst DNA polymerase, dNTPs, PBS buffer, FAM Probe and LFA test strip. The biosensor provided by the present invention can be used for preparing a product for detecting and judging influenza A (H1N1) virus. Compared with the traditional detection method, it only needs one primer and one template to obtain a higher amplification efficiency, is more convenient and rapid to operate, and has higher accuracy and sensitivity, solving the problems of the relatively complex detection process of H1N1 virus in the prior art and the limitations of isothermal technology in the prior art.

The invention discloses a CRISPR-Cas12a system H1N1 virus hypersensitive nucleic acid detection system and a kit and application thereof, the CRISPR-Cas12a system H1N1 virus hypersensitive nucleic acid detection system comprises a Cas12a recognition system, an allosteric regulation component, a signal amplification component and a report system, the system reduces background noise through allosteric inhibition, improves sensitivity through dual signal amplification, and realizes hypersensitive detection of an H1N1 virus M1 gene in combination with ErCas12a protease. The method has the advantages of low detection lower limit, no dependence on natural PAM sequence, less than 1 hour of time consumption and the like, and the sensitivity and the specificity are superior to those of the existing RT-qPCR detection method. By adjusting crRNA and probe sequences, the platform disclosed by the invention can be expanded for portable rapid detection of various respiratory pathogens, and is particularly suitable for primary medical treatment and field emergency screening.

FIELD: biotechnology.SUBSTANCE: plasmid DNA matrix pVAX-C3-H1-PolyA and the polynucleotide mRNA vaccine synthesized using the said DNA matrix pVAX-C3-H1-PolyA, encoding the hemagglutinin of the influenza A / H1N1 virus and ensuring its expression and induction of a specific immune response when introduced into the body of mammals, used in immunology, genetic engineering, biotechnology and medicine. A recombinant plasmid DNA matrix pVAX-C3-H1-PolyA was obtained, providing expression of mRNA in mammalian cells, having the nucleotide sequence SEQ ID NO: 1 with a size of 4849 bp, a molecular weight of 3.1 MDa and including a fragment of 1680 bp, having coordinates from 699 to 2378 bp and containing an artificial gene encoding the hemagglutinin protein of the influenza A / Wisconsin / 67 / 2022 (H1N1)pdm09 virus without the transmembrane and cytoplasmic domain with the addition of the trimerizing domain of phage T4 with the initiation codon ATG. An mRNA vaccine was obtained having the nucleotide sequence SEQ ID NO: 2, obtained using a DNA matrix and containing an open reading frame encoding the amino acid sequence SEQ ID NO:3 of the influenza virus hemagglutinin immunogen protein, and ensuring the synthesis and secretion of the said protein in the body of mammals.EFFECT: expansion of the range of more relevant mRNA vaccines against the influenza virus.2 cl, 6 dwg, 3 ex

A biological enzyme for killing viruses and a preparation method thereof are provided, which relate to the field of biotechnologies, and the biological enzyme is made from the following raw materials: Artemisia argyi, Lactuca sativa, Allium tuberosum, Allium cepiforme, Litsea rubescensLeeomte, Glycyrrhiza uralensis, Allium sativum, Mentha canadensis, Allium mongolicum, Lonicera japonica, Sargassum, monazite, calcium carbonate, fructo oligosaccharide (FOS), isomaltooligosaccharide (IMO) and organic selenium. The biological enzyme can be used for a H1N1 virus and its complications, and the biological enzyme does not harm beneficial fungi and cells of a human body, and makes up for deficiency that other antibiotics, drugs, disinfection and sterilization can not only kill bacteria and viruses, but also kill the beneficial fungi and cells.

The application discloses THK01 and derivatives thereof, a preparation method and application of the THK01 and the derivatives in preparation of anti-inflammatory drugs, and relates to the following steps: a series of chemical reactions, including Wittig reaction, Diels-Alder reaction, Cadogan reaction, Fischer indole synthesis reaction, demethylation reaction, reduction reaction and click chemistry reaction, are carried out on ortho-nitrobenzaldehyde containing specific substituents, so that THK01 structural modification derivatives with different substituents are obtained. The THK01 structural modification derivatives are synthesized in various routes, and the reaction success rate is high. In vitro and in vivo experiments show that the compounds can significantly inhibit the production of NO and inflammatory reactions at a low concentration, and can effectively treat inflammatory bowel disease and H1N1 virus-induced acute pneumonia in an animal model. The findings provide valuable candidate compounds and new treatment strategies for developing new, safe and efficient anti-inflammatory drugs.

The application provides a flavone glycoside with antiviral activity and a preparation method and application thereof. The structural formula of the flavone compound phloretin 3'-C-(2-O-trans-p-coumaroyl-3-O-beta-D-glucosyl)-beta-D-fucosyl-6'-O-(2-O-beta-D-fucosyl)-alpha-L-arabinofuranoside of the application is shown as formula (I), and the compound is isolated from dried or fresh products of fruits, stems or leaves of Averrhoa carambola. In vitro pharmacological experiments prove that the compound phloretin 3'-C-(2-O-trans-p-coumaroyl-3-O-beta-D-glucosyl)-beta-D-fucosyl-6'-O-(2-O-beta-D-fucosyl)-alpha-L-arabinofuranoside has good anti-H1N1 virus ability, and the EC 50 value thereof is 8.916 muM, indicating that the compound has good antiviral activity. The flavone compound phloretin 3'-C-(2-O-trans-p-coumaroyl-3-O-beta-D-glucosyl)-beta-D-fucosyl-6'-O-(2-O-beta-D-fucosyl)-alpha-L-arabinofuranoside is expected to be used as a lead compound to develop a new antiviral drug.